Boundless Bio, Inc. (BOLD) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-08

Key Insights

Boundless Bio announced Q1 2026 financial results on May 8, 2026, but the actual press release content with specific financial metrics is not included in this 8-K filing, limiting visibility into revenue, expenses, and operational performance.
The company is classified as an emerging growth company, which provides certain regulatory relief and exemptions from compliance requirements, suggesting it is still in a relatively early stage of development.
The filing is a standard 8-K disclosure under Item 2.02 (Results of Operations and Financial Condition) with no material agreements, leadership changes, or other significant events reported, indicating routine quarterly earnings announcement.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-13

Boundless Bio has terminated its lease agreement for its laboratory and office space in San Diego, California, effective May 31, 2026, which was originally set to expire on October 31, 2034.
The company has agreed to pay a $10 million lease modification payment and forfeit its $0.5 million security deposit as part of the lease termination agreement.
The termination of the lease agreement is subject to the landlord successfully leasing the premises to a new tenant, which has been satisfied.

Filed: 2026-03-09

Boundless Bio, Inc. reported its Q4 2025 and full-year 2025 financial results, showing continued growth and progress in its operations.
The company announced the resignation of Christine Brennan, Ph.D. from its Board of Directors, citing her acceptance of a new role at Johnson & Johnson Development Corporation.
The resignation of Dr. Brennan does not appear to be due to any disagreement with the company, suggesting an amicable departure.

Other reports for Boundless Bio, Inc.

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.